Table 1.
Afatinib-resistant cell lines and resistant mechanisms
| Cell lines | Method of drug exposure | EGFR T790M mutation | MET amplification | EMT | Stem cell markers |
|---|---|---|---|---|---|
| HCC827 | N/A | – | – | – | – |
| HCC827-AR1 | Stepwise, 10 nM | – | – | + | + |
| HCC827-AR2 | Intermittent (briefly), 2 μM | – | + | – | – |
| HCC827-ACR | Continuous, Crizotinib 0.2 μM | – | + | + | + |
| HCC827-AR3 | Stepwise, 1 nM | – | + | – | – |
| HCC827-AR4 | Intermittent (as long as possible), 2 μM | – | – | + | + |
| PC-9 | N/A | – | – | – | – |
| PC-9-AR1 | Stepwise, 10 nM | – | – | – | – |
| PC-9-AR2 | Intermittent (briefly), 2 μM | – | – | – | – |
| HCC4006 | N/A | – | – | – | – |
| HCC4006-AR1 | Stepwise, 10 nM | – | – | + | + |
| HCC4006-AR2 | Intermittent (briefly), 2 μM | – | – | + | – |
| HCC4011 | N/A | – | – | – | – |
| HCC4011-AR1 | Stepwise, 10 nM | – | + | – | – |
| HCC4011-AR2 | Intermittent (briefly), 2 μM | – | – | – | – |
EGFR, epidermal growth factor receptor; EMT, epithelial to mesenchymal transition; N/A, not applicable.